Background/Aims: Thromboembolic episodes are a frequent problem in end stage renal failure patients. The pathomechanism of the disorder is complex, including bioincompatibility of renal replacement therapy, endothelial dysfunction, increased blood level of procoagulant factors and uremic toxins. We studied changes in the functional properties of venous endothelial cells (VEC) in the presence of uremic serum and evaluated their possible modulation by N-acetylcysteine (NAC) or sulodexide (SUL). Methods: Serum samples from 12 uremic patients treated with hemodialysis were studied ex vivo on in vitro cultured VEC. In separate experiments, NAC 1 mmol/L or SUL 0.5 LRU/mL were added to uremic serum samples. Both changes in the gene expression and secretory activity of VEC were studied. Results: Uremic serum increased the expression of the following genes: IL6 +97%, p < 0.002; VEGF +28%, p < 0.002; vWF +47%, p < 0.002; PECAM +76%, p < 0.002; ICAM-1 +275%, p < 0.002; t-PA +96%, p < 0.002. Changes in gene expression were reflected by the increased secretory activity of VEC treated with the uremic serum. Exposure of VEC to uremic serum supplemented with NAC or SUL resulted in weaker stimulation of the studied genes' expression. Also, secretion of the studied solutes, with the exception of ICAM-1, was reduced in the presence of NAC: IL6 -34%, p < 0.01; VEGF -40%, p < 0.005; vWF -25%, p < 0.001; t-PA -47%, p < 0.01, and MMP9 -37%, p < 0.001. SUL reduced the uremic serum-induced secretion of all solutes: IL6 -24%, p < 0.05; ICAM-1 -43%, p < 0.01; VEGF -38%, p < 0.01; vWF -23%, p < 0.01; t-PA -49%, p < 0.01, and MMP9 -25%, p < 0.05. Conclusions: Uremic serum induces prothrombotic changes in VEC, which may cause a predisposition to thrombotic disorders in patients with renal failure. NAC and SUL reduce the effects of the uremic serum in VEC, which suggests their potential therapeutic application in uremic patients.
Introduction
Paradoxically, in patients with end stage renal failure, despite the increased risk of bleeding, thrombotic disorders are common, which may result in life-threatening situations such as pulmonary artery embolism [1] . The incidence of spontaneous venous thrombosis and pulmonary embolism increases proportionally to the progression of the renal failure [2] . In patients with end stage renal failure, there is also increased risk of thrombotic complications after endovascular procedures such as angioplasty [3] . The occurrence of deep vein thrombosis is higher in renal patients than in patients with other diseases, and the risk of such pathology is linked with activation of procoagulant markers, decreased anticoagulants, or enhanced platelet activation [4] .
There are several potential mechanisms leading to thrombotic disorders in renal patients, such as hemodialysis-induced platelet aggregation [5] , increased blood level of procoagulant factors [6] or uremic toxins [7] . Abnormal endothelial function can also contribute to the development of thrombotic events due to a damaged glycocalyx, which is a natural antithrombotic structure on the surface of these cells [8] , increased synthesis of tissue factor [9] or adhesion molecules [10] . Atherosclerotic changes in the arterial system can also accelerate the formation of intravascular thrombi due to the interaction between the blood clotting factors, platelets, and atherosclerotic plaques [11] .
Treatment of thrombotic disorders in renal patients is difficult due to the fact that uremia at the same time may impair the blood coagulation system. Furthermore, due to renal failure, the metabolism and excretion of drugs is altered. Low molecular weight heparin preparations, which are commonly used in the prevention of thromboembolic disease, may cause bleeding complications in renal patients [12] . Intravascular thrombosis in renal patients is induced through various mechanisms, and therefore, we should look for the most effective and at the same time safe treatment of that disorder. We present data from a study in which we evaluated the effect of uremic serum on function of venous endothelial cells (VEC) and tested two different substances, N-acetylcysteine and sulodexide, which can potentially modulate uremia-induced dysfunction of the endothelium.
Material and Methods
Experiments were performed on VEC in in vitro culture which were exposed to serum obtained from patients with end stage renal failure. The study was approved by the Ethical Committee at Poznan University of Medical Sciences. All 12 patients participating in the study gave their informed consent. Blood samples were collected before the start of the hemodialysis session. The mean age of the patients was 54.4 ± 5.2 years, the duration of renal replacement therapy was 41 ± 11 months, and GFR was 7.4 ± 3.1 mL/min. Diabetics, patients with acute or chronic inflammatory diseases or peripheral vein insufficiency were excluded from the study. Collected serum samples were stored at -86 ° C until they were used during the experiments.
The study was performed on in vitro cultured human umbilical vein endothelial cells (Life Technologies Corporation, Carlsbad, USA). Cells were cultured in medium M200 supplemented with 2% fetal bovine serum, heparin 10 µg/mL, hydrocortisone 1 µg/mL, basic fibroblast growth factor 3 ng/mL, and human epidermal growth factor 10 ng/mL. Experiments were performed on cell monolayers. Cells were exposed during 24 h to the studied media, and at the end of the incubation, the expression of the studied genes and the secretory activity of the cells were studied. The following experimental groups were studied: 1 Medium supplemented with 20% control serum 
Analysis of Gene Expression
Experiments were performed on VEC monolayers in 6-well plates. After 24 h incubation of the studied media, gene expression was studied in the cells. Gene expression analysis was calculated using the quantitative real-time PCR technique. Total RNAs from VEC were isolated using the ReliaPrep TM RNA Cell Miniprep System (Promega, USA) according to the manufacturer's protocol. After the treatment of RNA samples with DNase I (Ambion, USA), RNA concentrations were measured with a NanoDrop UV-Vis spectrophotometer (NanoDrop, Thermo Scientific, USA). The quality of the obtained RNA samples was determined by the PrimePCR RNA Quality SYBR Green Assay (Bio-Rad, USA).
From each sample, one microgram of total RNA was reverse-transcribed to cDNA using random primers from the iScript cDNA Synthesis Kit (Bio-Rad, USA). The relative expression levels of 7 genes of interest, Interleukin-6 (IL6), Von Willebrand Factor (vWF), Matrix Metallopeptidase 9 (MMP9), Vascular Endothelial Growth Factor A (VEGFA), Platelet and Endothelial Cell Adhesion Molecule 1 (PECAM1), Tissue Plasminogen Activator (t-PA), and Intercellular Adhesion Molecule 1 (ICAM-1), were analyzed in triplicate using SsoAdvanced TM Universal SYBR ® Green Supermix (Bio-Rad, USA) and normalized to levels of internal housekeeping genes Actin β (ACTβ), Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH), and Hypoxanthine-Guanine Phosphoribosyltransferase 1 (HRPT1). Sequence-specific primers of 7 genes of interest were designed using Primer3Plus [13] . The list of primers is presented in Table 1 .
The relative quantification of the expression of the selected genes was performed using Bio-Rad CFX96 equipment (Bio-Rad, USA). The reaction thermal conditions were 95 ° C for 30 s (polymerase activation) followed by 40 cycles of 95 ° C for 15 s (denaturation) and 60 ° C for 1 min (annealing and extension). The verification of the specificity of amplicons was performed by melting curve analysis. Relative quantification of gene expression was calculated for each sample by the 2 -ΔΔCT method [14] .
Evaluation of the Secretory Activity of VEC
Experiments were performed on the VEC monolayers in 24-well culture plates. Cells were exposed during 24 h to the studied media and then, during the following 24 h, to serum free medium for evaluation of their secretory activity. At the end of the incubation, medium from the wells was collected for measurement of the studied solutes: 
Statistical Analysis
Results are presented as mean + SD. Statistical analysis was performed with the Wilcoxon test or with one-way analysis of variance with the post hoc Newman Keuls test. A p value less than 0.05 was considered statistically significant.
Results
In vitro exposure of VEC to uremic serum caused increased expression of the studied genes as compared to cells treated with control serum: IL6 +97%, p < 0.002; VEGF +28%, p < 0.002; vWF +47%, p < 0.002; PECAM +76%, p < 0.002; ICAM-1 +275%, p < 0.002; t-PA +96%, p < 0.002 (Fig. 1) . Changes in gene expression were reflected by increased secretory activity of VEC treated with the uremic serum: IL6 +25%, p < 0.01; ICAM-1 +153%, p < 0.001; VEGF +49%, p < 0.005; vWF +44%, p < 0.01; t-PA +59%, p < 0.005, and MMP9 +861%, p < 0.001 ( Table 2) .
Exposure of VEC to uremic serum supplemented with N-acetylcysteine 1 mmol/L or sulodexide 0.5 LRU/mL resulted in weaker stimulation of the studied gene expression (Fig. 2) . Also, secretion of the studied solutes, with the exception of ICAM-1, was reduced in the presence of N-acetylcysteine 1 mmol/L: IL6 -34%, p < 0.01; VEGF -40%, p < 0.005; vWF -25%, p < 0.001; t-PA -47%, p < 0.01, and MMP9 -37%, p < 0.001. Sulodexide 0.5 LRU/mL reduced the uremic serum-induced secretion of all solutes: IL6 -24%, p < 0.05; ICAM-1 -43%, p < 0.01; VEGF -38%, p < 0.01; vWF -23%, p < 0.01; t-PA -49%, p < 0.01, and MMP9 -25%, p < 0.05 (Fig. 3, 4) .
Discussion
The presented results confirm that VEC, after exposure to uremic serum, acquire the prothrombotic genotype and phenotype. Previously, Chitalia and co-workers [15] demonstrated that uremic serum augmented the expression of tissue factor in vascular smooth muscle cells, which resulted in increased thrombotic risk. The increased expression and secretory activity of VEC observed in our study may enhance the risk of thrombotic disorders due to the high levels of IL6 [16] , ICAM-1 [17] , vWF [18] , and MMP9 [19] . Our results suggest that abnormal function of the VEC during uremia plays an important role in the development of thrombotic disorders. At the same time, in end stage renal failure patients, there are other risk factors typical for that population leading to thrombosis, such as bioincompatibility of hemodialysis membranes or administration of recombinant erythropoietin [1] . Therefore, there is a need for the effective treatment of thrombotic disorders in that group of patients, which, however, is not easy because of the multiple disorders caused by renal failure which can interfere with the applied therapy [20] . The results of our study suggest that both N-acetylcysteine and sulodexide significantly reverse the prothrombotic state of VEC, which may result in the reduction of thrombotic disorders in uremic patients. N-acetylcysteine efficiency in the treatment of intravascular thrombi has been shown before. Martinez de Lizarrondo and co-workers [21] demonstrated that intravenously administered N-acetylcysteine has a thrombolytic effect on arterial thrombi, and its action depends on reducing the bisulfide bridges in large vWF multimers, which results in platelet disaggregation. Our results show that N-acetylcysteine reduces the synthesis of vWF in VEC (Fig. 4) , which enhances its antithrombotic effect. In another study, the inhibiting action of N-acetylcysteine on platelet activation was found, which also results in the antithrombotic effect of that drug [22] . Our results show that N-acetylcysteine reduces the expression of PECAM1 in endothelial cells (Fig. 2) , which may also decrease the interaction of platelets with the endothelium and the formation of thrombi. The results of our study demonstrating the inhibiting effect of N-acetylcysteine on uremic serum-induced synthesis in the EVC of IL6, MMP9, and vWF show the complexity of the antithrombotic effect of N-acetylcysteine on the level of the venous endothelium. The validity of N-acetylcysteine as an antithrombotic agent was also confirmed in a patient with multiple venous and arterial thrombotic events which were resistant to conventional therapy [23] . However, that was an observation made in one patient, and further studies are required to confirm the validity of N-acetylcysteine in the treatment of thrombotic disorders in uremic patients.
Sulodexide, as with N-acetylcysteine, reduced the prothrombotic changes in VEC exposed to uremic serum in our experiments. Both gene expression and secretion of IL6, ICAM-1, vWF, and MMP9 were reduced, and all these effects in in vivo conditions may translate into a lower risk of intravascular thrombosis (Fig. 2-4 ). Sulodexide's efficiency in the prevention of deep vein thrombosis is well known and was confirmed in many clinical studies [24] . In our previous studies, we demonstrated that the antithrombotic action of sulodexide is linked with its antioxidant and anti-inflammatory effects on the level of the venous endothelium [25, 26] . The results of the present study show that sulodexide may also be effective in the prevention of thromboembolic disorders in a group of patients with end stage renal failure. An important disorder which can increase the risk of intravascular thrombosis is damage to the glycocalyx, observed in patients on renal replacement therapy [8] . Dysfunction of the glycocalyx leads to many disorders, such as increased capillary permeability and interaction of the endothelium with leukocytes and platelets, which predisposes patients to intravascular thrombosis [27] . Chronic administration of sulodexide, which is a mixture of glycosaminoglycans present in the glycocalyx, results in the rebuilding of that structure [28] . Normal structure of the glyco- calyx together with reduced expression of PECAM and ICAM-1 in the presence of sulodexide observed in our experiments can significantly reduce interactions between the vascular endothelium, leukocytes, and platelets, which will result in lower risk of intravascular thrombosis.
In conclusion, we found that in the uremic milieu, VEC acquire the prothrombotic genotype and phenotype, which may predispose patients to thromboembolic disorders in end stage renal failure. Both N-acetylcysteine and sulodexide reduce the uremic seruminduced changes in the endothelial cells, which must result in reduced risk of thrombosis in that group of patients. The structure of both tested substances is totally different, and one can assume that these substances can induce the additive antithrombotic effect in uremic patients. Further studies are required to confirm this hypothesis.
